KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt to Equity (2019 - 2025)

Historic Debt to Equity for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $0.93.

  • Royalty Pharma's Debt to Equity rose 2538.61% to $0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.93, marking a year-over-year increase of 2538.61%. This contributed to the annual value of $0.74 for FY2024, which is 2098.0% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Debt to Equity is $0.93, which was up 2538.61% from $0.84 recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Debt to Equity ranged from a high of $0.93 in Q3 2025 and a low of $0.57 during Q2 2021
  • For the 5-year period, Royalty Pharma's Debt to Equity averaged around $0.71, with its median value being $0.71 (2022).
  • As far as peak fluctuations go, Royalty Pharma's Debt to Equity plummeted by 1856.41% in 2023, and later surged by 2538.61% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Debt to Equity stood at $0.7 in 2021, then rose by 6.28% to $0.75 in 2022, then dropped by 18.56% to $0.61 in 2023, then grew by 20.98% to $0.74 in 2024, then rose by 26.33% to $0.93 in 2025.
  • Its last three reported values are $0.93 in Q3 2025, $0.84 for Q2 2025, and $0.78 during Q1 2025.